این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Nanomedicine Journal، جلد ۱۱، شماره ۴، صفحات ۴۰۱-۴۱۶
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Quality by design enabled formulation development of regorafenib monohydrate loaded PEGylated PLGA polymeric nanoparticles: Enhanced oral bioavailability and biopharmaceutical attributes
چکیده انگلیسی مقاله Objective(s): Using a quality-by-design methodology, the current research is aimed to prepare and enhance the PEGylated PLGA-loaded regorafenib monohydrate polymeric nanoparticles for enhancing oral bioavailability and biopharmaceutical attributes. The oral multi-kinase inhibitor inhibits VEGFR2-TIE2 tyrosine kinases on two separate targets, which results in anti-angiogenic activity. It also inhibits stromal and oncogenic receptor tyrosine kinases. Materials and Methods: The current study developed nanosized, biocompatible, and PEGylated PLGA polymeric nanoparticles to administer regorafenib monohydrate to patients with metastatic colon cancer. This was accomplished using a modified nanoprecipitation technique to make drug-encapsulated PEGylated PLGA nanoparticles with poloxamer 188 as a stabilizer. Results: The polymeric nanoformulations were characterized for zeta potential, distribution of particle size, entrapment efficiency, DSC, FT-IR, X-RD, and SEM. Both in vitro and in vivo experimental studies were performed for the pure drug and the improved nanoparticle formulation.Conclusion: The nanoparticles obtained from optimization studies  were found to have smaller particle sizes, higher entrapment efficiency (%), drug loading capacity, spherical shape particles, amorphous drug embedded matrix, and a biphasic delayed release pattern. These findings suggest that drug-loaded PEGylated PLGA nanoparticles are a potent formulation for the treatment of colon cancer, with improved oral bioavailability and biopharmaceutical properties.
کلیدواژه‌های انگلیسی مقاله Bioavailability potential, Polymeric nanoparticles, Quality by design, Regorafenib monohydrate, Zeta potential  
نویسندگان مقاله | Dhananjay Panigrahi
School of Pharmaceutical Sciences (SPS), Siksha O Anusandhan Deemed to be University, Kalinga Nagar, Ghatikia, Bhubaneswar-751029, Odisha, India


| Suryakanta Swain
Amity Institute of Pharmacy, Amity University, Major Arterial Road, AA II, Newtown, Kadampukur, Kolkata-700135, West Bengal, India


| Pratap Sahu
School of Pharmaceutical Sciences (SPS), Siksha O Anusandhan Deemed to be University, Kalinga Nagar, Ghatikia, Bhubaneswar-751029, Odisha, India


| Debashish Ghose
Department of Pharmaceutics, Roland Institute of Pharmaceutical Sciences, Berhampur-760010, Odisha, India


| Bikash Ranjan Jena
School of Pharmacy and Life Science, Centurion University of Technology and Management Bhubaneswar-751009, Odisha, India
نشانی اینترنتی https://nmj.mums.ac.ir/article_24729.html
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده مقاله پژوهشی
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات